Literature DB >> 29608096

Reporting non-adherence in cluster randomised trials: A systematic review.

Schadrac C Agbla1, Karla DiazOrdaz1.   

Abstract

BACKGROUND: Treatment non-adherence in randomised trials refers to situations where some participants do not receive their allocated treatment as intended. For cluster randomised trials, where the unit of randomisation is a group of participants, non-adherence may occur at the cluster or individual level. When non-adherence occurs, randomisation no longer guarantees that the relationship between treatment receipt and outcome is unconfounded, and the power to detect the treatment effects in intention-to-treat analysis may be reduced. Thus, recording adherence and estimating the causal treatment effect adequately are of interest for clinical trials.
OBJECTIVES: To assess the extent of reporting of non-adherence issues in published cluster trials and to establish which methods are currently being used for addressing non-adherence, if any, and whether clustering is accounted for in these.
METHODS: We systematically reviewed 132 cluster trials published in English in 2011 previously identified through a search in PubMed.
RESULTS: One-hundred and twenty three cluster trials were included in this systematic review. Non-adherence was reported in 56 cluster trials. Among these, 19 reported a treatment efficacy estimate: per protocol in 15 and as treated in 4. No study discussed the assumptions made by these methods, their plausibility or the sensitivity of the results to deviations from these assumptions. LIMITATIONS: The year of publication of the cluster trials included in this review (2011) could be considered a limitation of this study; however, no new guidelines regarding the reporting and the handling of non-adherence for cluster trials have been published since. In addition, a single reviewer undertook the data extraction. To mitigate this, a second reviewer conducted a validation of the extraction process on 15 randomly selected reports. Agreement was satisfactory (93%).
CONCLUSION: Despite the recommendations of the Consolidated Standards of Reporting Trials statement extension to cluster randomised trials, treatment adherence is under-reported. Among the trials providing adherence information, there was substantial variation in how adherence was defined, handled and reported. Researchers should discuss the assumptions required for the results to be interpreted causally and whether these are scientifically plausible in their studies. Sensitivity analyses to study the robustness of the results to departures from these assumptions should be performed.

Entities:  

Keywords:  Non-adherence; causal treatment effect; cluster randomised trials; trial reporting

Mesh:

Year:  2018        PMID: 29608096      PMCID: PMC6485377          DOI: 10.1177/1740774518761666

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  51 in total

1.  Principal stratification in causal inference.

Authors:  Constantine E Frangakis; Donald B Rubin
Journal:  Biometrics       Date:  2002-03       Impact factor: 2.571

2.  The compliance score as a regressor in randomized trials.

Authors:  Marshall M Joffe; Thomas R Ten Have; Colleen Brensinger
Journal:  Biostatistics       Date:  2003-07       Impact factor: 5.899

3.  Clustered encouragement designs with individual noncompliance: bayesian inference with randomization, and application to advance directive forms.

Authors:  Constantine E Frangakis; Donald B Rubin; Xiao-Hua Zhou
Journal:  Biostatistics       Date:  2002-06       Impact factor: 5.899

4.  Assessing the effect of an influenza vaccine in an encouragement design.

Authors:  K Hirano; G W Imbens; D B Rubin; X H Zhou
Journal:  Biostatistics       Date:  2000-03       Impact factor: 5.899

5.  CONSORT statement: extension to cluster randomised trials.

Authors:  Marion K Campbell; Diana R Elbourne; Douglas G Altman
Journal:  BMJ       Date:  2004-03-20

6.  Pitfalls of and controversies in cluster randomization trials.

Authors:  Allan Donner; Neil Klar
Journal:  Am J Public Health       Date:  2004-03       Impact factor: 9.308

Review 7.  Lessons for cluster randomized trials in the twenty-first century: a systematic review of trials in primary care.

Authors:  Sandra M Eldridge; Deborah Ashby; Gene S Feder; Alicja R Rudnicka; Obioha C Ukoumunne
Journal:  Clin Trials       Date:  2004-02       Impact factor: 2.486

8.  Uses and limitations of randomization-based efficacy estimators.

Authors:  Ian R White
Journal:  Stat Methods Med Res       Date:  2005-08       Impact factor: 3.021

9.  An introduction to causal modeling in clinical trials.

Authors:  Scarlett L Bellamy; Julia Y Lin; Thomas R Ten Have
Journal:  Clin Trials       Date:  2007       Impact factor: 2.486

10.  Sample size slippages in randomised trials: exclusions and the lost and wayward.

Authors:  Kenneth F Schulz; David A Grimes
Journal:  Lancet       Date:  2002-03-02       Impact factor: 79.321

View more
  4 in total

1.  Influential methods reports for group-randomized trials and related designs.

Authors:  David M Murray
Journal:  Clin Trials       Date:  2022-01-06       Impact factor: 2.599

2.  What are the statistical implications of treatment non-compliance in cluster randomized trials: A simulation study.

Authors:  Mirjam Moerbeek; Sander van Schie
Journal:  Stat Med       Date:  2019-10-03       Impact factor: 2.373

3.  Safe birth in cultural safety in southern Mexico: a pragmatic non-inferiority cluster-randomised controlled trial.

Authors:  Iván Sarmiento; Sergio Paredes-Solís; Abraham de Jesús García; Nadia Maciel Paulino; Felipe René Serrano de Los Santos; José Legorreta-Soberanis; Germán Zuluaga; Anne Cockcroft; Neil Andersson
Journal:  BMC Pregnancy Childbirth       Date:  2022-01-17       Impact factor: 3.007

Review 4.  Statistical analysis of publicly funded cluster randomised controlled trials: a review of the National Institute for Health Research Journals Library.

Authors:  Bright C Offorha; Stephen J Walters; Richard M Jacques
Journal:  Trials       Date:  2022-02-04       Impact factor: 2.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.